Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.42 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30240849 | 1.00 | KMT2A (0.56) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL3996930 | 0.84 | KMT2A (0.53) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL29866123 | 0.84 | KMT2A (0.53) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL322040 | 0.84 | KMT2A (0.53) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL7044973 | 0.82 | FOLH1 (0.62) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL929805 | 0.82 | LOXL2 (0.60) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL3276164 | 0.82 | KMT2A (0.51) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL2537972 | 0.82 | KMT2A (0.51) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL29866166 | 0.82 | KMT2A (0.51) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 | |
| SCHEMBL10268514 | 0.81 | KMT2A (0.50) | KMT2AMEN1L3MBTL1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2024-10-31 | — | — | US | disclosed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-11174261-B2 | — | — | 2021-11-16 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-03-19 | — | — | US | disclosed |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| WO-2018049145-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | CALITHERA BIOSCIENCES, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070197608-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| EP-1660501-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| WO-2005023812-A2 | PIPERAZINES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2005-03-17 | — | — | WO | disclosed |
| EP-1512687-A1 | Piperazines as oxytocin agonists | FERRING B.V. (NL) | 2005-03-09 | — | — | EP | disclosed |
| US-6492384-B1 | Imidazo (4,5-C) pyridine-4-one derivatives with factor XA inhibiting effect | MERCK PATENT GMBH (DE) | 2002-12-10 | — | — | US | disclosed |
| EP-1117664-A1 | IMIDAZO[4,5-C-]-PYRIDINE-4-ONE DERIVATIVES WITH FACTOR XA INHIBITING EFFECT | MERCK PATENT GmbH (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000020416-A1 | IMIDAZO[4,5-C-]-PYRIDINE-4-ONE DERIVATIVES WITH FACTOR XA INHIBITING EFFECT | MERCK PATENT GMBH (DE) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | KMT2A 3055/4885MEN1 1731/4885L3MBTL1 4683/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | KMT2A 3055/4885MEN1 1731/4885L3MBTL1 4683/4885 |
| US-11174261-B2 | — | ENTPD5, NT5E, ENTPD1 | KMT2A 2482/4885MEN1 1397/4885L3MBTL1 4421/4885 |
| US-11208414-B2 | Ectonucleotidase inhibitors and methods of use thereof | ENTPD5, NT5E, ENTPD1 | KMT2A 2369/4885MEN1 1545/4885L3MBTL1 4479/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | KMT2A 3055/4885MEN1 1731/4885L3MBTL1 4683/4885 |
| US-20200087310-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | KMT2A 3055/4885MEN1 1731/4885L3MBTL1 4683/4885 |
| US-20070197608-A1 | Piperazines as oxytocin agonists | OXTR, OPRL1, AVPR2 | KMT2A 4438/4885MEN1 3461/4885L3MBTL1 4558/4885 |
| US-20240360082-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | PNPO, PDXK, PLPBP | KMT2A 3700/4885MEN1 1958/4885L3MBTL1 3906/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | KMT2A 3055/4885MEN1 1731/4885L3MBTL1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.